Going concern uncertainty
The company has reported negative operating cash flow and limited cash resources, creating doubt about its ability to fund operations.
- Scope
- Corporate liquidity and continuity of operations
- Materiality
- high
Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company organized around prescription erectile dysfunction products and related men’s health devices. The company has operated through subsidiaries including Metuchen Pharmaceuticals, Timm Medical Technologies, and Pos-T-Vac, with activities historically centered on Stendra® and vacuum erection devices.
2.25
2.25
| % | |
|---|---|
| Prescription ED Pharmaceuticals | 60% Prescription erectile dysfunction therapy historically commercialized under the Stendra® brand. |
| Vacuum Erection Devices | 35% Mechanical erectile dysfunction devices sold through Timm Medical and Pos-T-Vac. |
| Self-Care OTC / ACNU Development | 5% Development efforts aimed at nonprescription pharmaceutical products and ACNU treatments. |
The company’s historical customers include adult men seeking treatment for erectile dysfunction through prescription or...
- ED patientsprimary
Men seeking prescription or device-based erectile dysfunction treatment.
- Wholesalers and distributorsprimary
Buy and distribute Stendra® and related pharmaceutical products through commercial channels.
- Retail/device channelssecondary
Purchase VED products for resale to men’s health consumers.
- OTC/self-care consumersemerging
Future target users for nonprescription pharmaceutical products and ACNU offerings.
Petros is a U.S.-based company with operations and commercial activity historically centered in the United States...
- •Headquartered in the United States
- •Commercial activity historically centered in U.S. markets
- •Subsidiaries support pharmaceutical and device operations
- •Distribution has relied on U.S. wholesale and retail channels
Petros is repositioning its business toward nonprescription pharmaceuticals and ACNU products while evaluating internal...
01
Build a nonprescription product platformmedium-term
The company is trying to replace legacy ED revenue with self-care products that can be commercialized through broader consumer channels.
02
Pursue collaborations and acquisitionsmedium-term
External deals can add products, rights, or capabilities faster than internal development alone.
03
Secure financingshort-term
Development and commercialization require capital before new products can generate meaningful revenue.
Petros faces substantial going-concern and financing risk because it has limited operating resources and depends on...
Need for additional capital
Development and commercialization require funding before new products can generate cash flow.
- Scope
- Equity dilution, debt burden, or reduced activity
- Materiality
- high
Transition away from legacy revenue streams
Historical ED and device businesses were discontinued or assigned, removing established revenue sources.
- Scope
- Revenue base and operating scale
- Materiality
- high
Regulatory and commercialization risk
OTC/nonprescription pharmaceutical products require regulatory clearance and market acceptance.
- Scope
- Product launch timing and adoption
- Materiality
- high
OTC market liquidity and delisting risk
Trading on OTC markets can reduce liquidity and investor access compared with a national exchange.
- Scope
- Capital raising and share price volatility
- Materiality
- medium
Discontinued operations
Affects comparability of current-period results
Going concern assessment
Influences disclosure and asset/liability presentation
Contingencies and litigation estimates
May affect reserves and expense recognition
Settlement accounting
Can create one-time gains or balance-sheet reclassifications
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
IONIS PHARMACEUTICALS INC
IONS · Pharmaceutical Preparations
Ionis Pharmaceuticals is a U.S.-based biotechnology company focused on RNA-targeted medicines, using antisense chemistry to discover and develop therapies for serious diseases.
RHYTHM PHARMACEUTICALS, INC.
RYTM · Pharmaceutical Preparations
Rhythm Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for rare genetic disorders of obesity and related metabolic diseases.
GERON CORP
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Pelthos Therapeutics Inc.
PTHS · Biological Products, (No Diagnostic Substances)
Phathom Pharmaceuticals, Inc.
PHAT · Pharmaceutical Preparations
Phathom Pharmaceuticals is a U.S.-based biopharmaceutical company focused on developing and commercializing vonoprazan-based therapies for acid-related gastrointestinal diseases.
: 29.4.2026